Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC)

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1333-1342

  Singh, Rashmi Bhat ^a   Amare Kadam, Pratibha S ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

3p deletions; BAC array FISH; Comparative allelotyping; Conventional renal cell carcinoma (cRCC); LOH

Indexed keywords

VON HIPPEL LINDAU PROTEIN;

ARTICLE; BLADDER TUMOR; BREAST CARCINOMA; BREAST TUMOR; CANCER STAGING; CHROMOSOME 3; CHROMOSOME 3P; CLINICAL ARTICLE; FOLLOW UP; GENE DELETION; GENE PROBE; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INTERPHASE; KIDNEY CARCINOMA; LUNG TUMOR; MARKER GENE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

3P DELETIONS; BAC ARRAY-FISH; COMPARATIVE ALLELOTYPING; CONVENTIONAL RENAL CELL CARCINOMA (CRCC); LOH;

ACID ANHYDRIDE HYDROLASES; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN, PAIR 3; GENES, TUMOR SUPPRESSOR; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MICROSATELLITE REPEATS; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; URINARY BLADDER NEOPLASMS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84884672726     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.08.012     Document Type: Article

References (24)

1. Kovacs G., Erlandsson R., Boldog F., et al. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci U S A 1989, 85:1571-1575.
2. Velickovic M., Delahunt B., Grebe S.K. Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus. Cancer Res 1999, 59:1323-1326.
3. Braga E., Pugacheva E., Bazov I., et al. Comparative allelotyping of the short arm human chromosome 3 in epithelial tumors of 4 different types. FEBS Lett 1999, 454:215-219.
4. Lubinski J., Hadaczek P., Podolski J., et al. Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas. Cancer Res 1994, 54:3710-3713.
5. Sukosd F., Kuroda N., Beothe T., et al. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res 2003, 63:455-457.
6. Kim W., Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4993-5004.
7. Linehan W.M., Grubb R.L., Coleman J.A., et al. The genetic basis of kidney cancer: Implications for gene-specific clinical management. BJU Int 2005, 95(Suppl):2-7.
8. Skolarikos A.A., Papatsoris A.G., Alivizatos G., et al. Molecular pathogenenetics of renal cancer. Am J Nephrology 2006, 26:218-231.
9. Gnarra J.R., Tory K., Weng Y., et al. Mutation of the VHL tumor suppressor gene in renal cell carcinoma. Nat Genet 1994, 7:85-90.
10. Martinez A., Fullwood P., Kondo K., et al. Role of chromosome 3p12-p21 tumor suppressor genes in clear cell renal cell carcinoma: Analysis of VHL dependent and VHL independent pathways of tumorigenesis. Mol Pathol 2000, 53:137-144.
11. Woodward E.R., Clifford S.C., Astuti D., et al. Familial clear cell renal cell carcinoma (FCRC): Clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet 2000, 37:348-353.
12. Clifford S.C., Prowse A.H., Affara N.A., et al. Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL independent pathway in clear cell renal tumorigenesis. Genes Chromosomes Cancer 1998, 22:200-209.
13. Sanchez Y., el-Naggar A., Pathak S., et al. A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. Proc Natl Acad Sci U S A 1994, 91:3383-3387.
14. Killary A.M., Wolf E.M., Giambernardi T.A., et al. Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci U S A 1992, 89:10877-10881.
15. Amare Kadam P.S., Varghese C., Bharde S., et al. Proliferating cell nuclear antigen(PCNA) and epidermal growth factor receptor (EGFr) in renal cell carcinoma (RCC) patients with polysomy of chromosome 7. Cancer Genet Cytogenet 2000, 125:59-66.
16. Gemmill R.M., Chumakov I., Scott P., et al. A second-generation YAC contig map of human chromosome 3. Nature 1995, 377(Suppl):299-319.
17. Amare P.S., Ghule P., Jose J., et al. Constitutional genomic instability, chromosome aberrations in tumor cells, and retinoblastoma. Cancer Genet Cytogenetics 2004, 150:33-43.
18. Pais A., Amare P.S., Raje G., et al. Identification of various MLL gene aberrations that lead to MLL gene mutation in patients with acute lymphoblastic leukemia (ALL) and infants with acute leukemia. Leukemia Res 2005, 29:517-526.
19. Bhat Singh R.R., Amare Kadam P.S. Investigation of recurrent deletion loci specific to conventional renal cell carcinoma (cRCC) by comparative allelotyping in major epithelial carcinomas. Ind J Urol 2011, in press.
20. Braga E., Senchenko V., Bazov I., et al. Critical TSG regions on chromosome 3p in major human epithelial malignancies: Allelotyping and quantitative real-time PCR. Int J Cancer 2002, 100:534-541.
21. Roylance R., Gorman P., Harris W., et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 1999, 59:1433-1436.
22. Martinez A., Walker R.A., Shaw J.A., et al. Chromosome 3p allele loss in early invasive breast cancer: Detailed mapping and association with clinicopathologic features. Mol Pathol 2001, 54:300-306.
23. Maitra A., Wistuba I.I., Washington C., et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 2001, 159:119-130.
24. Zhang S.Y., Liu S.C., Al-Saleem L.F., et al. E2F-1: A proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 2000, 9:395-401.